About Biotech Insider Alert

Biotech Insider Alert is a powerful new service for investors. It tracks the most crucial milestones in a new drug or medical technology’s journey to the marketplace – and shows you how to invest for maximum gains. A longtime bioscience investing expert, editor Ernie Tremblay has a proven ability to identify only the companies that have likely breakthrough winners in the fast-moving bioscience sector. He pinpoints the exact calendar date the pharmaceutical company behind a new therapy can skyrocket in value. These stocks often pop by double and triple digits overnight, then run up to even bigger gains in the months ahead. It’s happened thousands of times. And now you can be one of the “insiders” grabbing those bioscience profits for yourself. Click here to see the latest news in biotech stock.

I’m here with urgent news about an altogether NEW breakthrough just “greenlighted” by the U.S. Government.

It’s a breakthrough so big, it has the power to create an entirely new industry.

An industry that could be worth not just hundreds of billions of dollars – but over $1 trillion.

It’s so new, so fresh, and so burgeoning that it didn’t even officially exist until 1:22 p.m. Eastern Standard Time on June 25, to be precise…

It’s an “offshoot” of the blistering hot marijuana business… and yet it’s 111 times larger.

Even better, it’s 100% legal and has NOTHING to do with marijuana as you know it…

Nothing to do with the stuff people smoke or vape to get high.

Nothing to do with edibles.

Nothing to do with medical marijuana you buy at dispensaries.

Nothing to do with growing, distributing, or selling it.

Nothing to do with the “pick and shovel” suppliers to the marijuana industry.

Nothing to do with the legalization in Canada… or California… or any other state or country that will legalize recreational marijuana in the future.

This is altogether different…

It’s new, and…

Much, much bigger.

Here’s what I mean…

The total size of the marijuana industry you know today is right around $10 billion…

Companies in the new industry I’ll tell you about today are now tapping into a $1.112 trillion market.

111 times bigger to be exact!

So why is this new “offshoot” industry expected to dwarf traditional marijuana markets?

It’s all about the numbers.

The products generated by this new industry could command as much as 21 timesthe price of regular, recreational marijuana.

And the market for this industry…

My research shows it could reach as many as 227 million regular Americans every year… and as many as 1.2 billion people around the world.

That’s a brand-new customer base, six times greater than the size of the pothead market…

And as you’ll see in a moment, they’ll be willing and happy to pay the higher price. In fact, I would wager that most of these folks would gladly pay any price, as you’re about to see.

So not only could it cost up to 21 times more… and have six times the customers…

It’ll be manufactured by billion-dollar companies skilled at bringing products to market – and handing massive gains to shareholders. In some instances, we’re talking about 10, 12, 14 times the investment.

In other words, it’s a “for real” industry, 100% legal… and made possible by the growing research in marijuana.

With all this new profit up for grabs, top business leaders are going to move fast – with many investing millions of their own money in groundbreaking new products.

And oh yes, I’m positive that banks and other institutions with huge bucks can – and will – now do major business in this industry.

And get this: It’s attracting some of the best experts, technicians and scientists in the world.

Politicians and government agencies are starting to support it in a MAJOR way.

It’s moving very fast…

With the potential to go from zero to billions, within the next 18 months alone.

Business Insider calls the June 25 event that created this opportunity a “sea change” for the industry.

Investor’s Business Daily called it “a historic milestone.”

In short, this has all the hallmarks of an opportunity capable of creating “generational” wealth…

On par with the legendary railroad barons of the late 1800s… 1900s Texas oilmen… and the Silicon Valley billionaires of the 2000s.

In fact, it’s set to be 10 times bigger than the entire oil industry in the U.S.!

For anyone who gets in on the ground floor, this is truly a historic opportunity to get rich.

If you missed out on the gains made from ordinary marijuana stocks…

When a small $2,500 stake would have soared to extraordinary gains as high as…

$397,500…

$947,500…

$1,588,500…

$6,225,000…

Even a rare, but astonishing $12,479,000…

Get ready…

A second, bigger opportunity is unfolding in this NEW industry as I speak.

Everything you’ve seen so far…

It’s all about to pale by comparison to what I’m about to share with you today.

If you’re in your 50s or 60s – and you’re worried about having enough money to retire anytime soon…

What I’m going to show you today has the potential to turn a small stake into the multimillion-dollar retirement of your dreams.

If you’re younger – this is your shot at the kind of massive wealth-building opportunity you may never see again.

And I’ll introduce you to some of the companies from this new industry that can make you rich.

For example…

You’ll hear the amazing story of one man who’s biggest “creation” became a household name and generated $35 billion in sales…

Now his new “product” – made possible by the marijuana market – is poised to revolutionize a $70 billion industry…

End a crisis that’s crippling our nation…

And potentially turn every $2,500 you invest into $231,400 or more.

I’ll also tell you about another company that recently received a rare and highly-coveted “designation” from the U.S. Government…

Which could turn another small $2,500 stake into $149,300.

Another tiny company I’ll tell you about just made an announcement that could set it on the path to a 351-fold explosion in growth…

And turn every $2,500 stake into a life-altering $877,500.

That’s just three companies – and the potential for over $1.2 million in gains.

All because of the greenlight the U.S. Government granted to create this new “offshoot” in this industry.

Of course, there are no guarantees the gains here will go this high. Anything can happen. And smaller companies in new industries like this one carry considerable risk.

But even half or a quarter of those gains would be life-changing…

We’ve seen how new events in the fledgling marijuana industry can drive small, unknown companies through the roof in a flash.

Canopy Growth Corporation was 5 cents a share heading into March of 2014…

As legal marijuana in Colorado became a reality and U.S. state support for medical marijuana started gaining steam…

Just 10 days later, it’s $3.37 a share. That’s a quick 6,600% gain.

There’s another quick jump here, in late 2016…

After Justin Trudeau announces his support for legalizing marijuana across Canada.

Canopy went from under $4 a share to $12.60… a quick triple in a few weeks…

Then again, ahead of California’s January 1 legalization…

When Canopy’s stock shot from $7.83 a share to a high of $37.48 in January…

For another fast 378% win.

Add it all together and that’s a massive 74,860% gain – driven by four crucial events…

Enough to turn $2,500 into over $1.87 million!

Of course, medical marijuana, legalization in Colorado, California, and Canada – these are important milestones in marijuana’s emergence as a massive growth industry…

But remember…

Even though the new industry I’ll tell you about today exists because of cannabis’s unprecedented growth…

This “offshoot” industry is completely new, legal… and has the potential to be 111 times bigger.

Yet, incredibly, very few know about it yet.

Which is GREAT for you.

Because today I’m going to lay everything out for you.

I’ll tell you what’s happening…

Detail the June event that launched this massive new industry…

And reveal five companies I’m following right now with the potential to turn a very small stake – into a combined $2.33 million.

One of the greatest thrills any investor can have is to find a tiny stock that’s trading for pennies a share…

And watch it quickly soar to $3… $5… $10… $20 and beyond.

Now imagine doing that not once… not twice… not five times…

But dozens of times.

That’s what I believe is about to happen here.

In fact, I’m so certain companies in this cannabis offshoot industry are going to soar…

I’ll guarantee you’ll have the opportunity to make at least 10 times your money with the NEXT wave –all within a year’s time.

There’s not a chance in the world I could make such a bold promise with ordinary speculations.

But now that this new breakthrough just greenlighted by the U.S. Government has been unleashed…

With six times the potential customers… who could spend as much as 21 times more than recreational marijuana users…

I believe the biggest gains are yet to come.

Now, before I give you all the details, let me introduce myself.

Again, my name is Ernie Tremblay…

I’m the Chief Scientific Researcher here at Money Morning.

My job is to give you the latest groundbreaking developments in medical science and biotechnology – and show you how to profit.

I was raised in the medical field.

My father was a primary care physician.

My mother, a registered nurse.

My brother, a highly respected cardiologist.

Me, I chose to follow and report on the latest and most exciting medical research.

I’ve spent over three decades studying the science behind new treatments for pain, cancer, Alzheimer’s, cardiovascular disease and more.

I’ve worked with Nobel-caliber physicians like Doctors Karel Liem and William S. Beck of Harvard, as well as Dr. George Gaylord Simpson of Columbia, helping them develop their published work.

I’ve written and contributed to more than 100 publications in the medical field for top publishers such as Prentice Hall and Harper Collins.

After 30 years in the field, I “get” the hard science behind new and experimental drugs.

For me, finding companies that can make you money really just comes down to three questions:

Does the science behind the drug work?

Is there a need?

And will doctors prescribe it?

Let me give you a good example…

Dravet syndrome is a catastrophic form of epilepsy that shows up in babies.

There’s no cure and nearly 20% die from severe seizures and related causes.

A few months back, my research led me to a small biotech where the only drug in its pipeline resulted in 7 out of 10 test patients being “seizure free” for at least a year.

So I recommended Zogenix Inc. a few weeks ahead of this important data release when it was trading at $14.25…

Within a month, the stock had doubled to $38.90 on the way to an eventual high of $45.25…

That’s one example.

While working on cardiovascular research, I came across a small company doing amazing work in the area of arterial disease. I recommended it and within three months it soared from $35 to $114…

Another company I was following developed a breakthrough treatment for HIV.

I wrote about the drug’s massive potential and recommended Sangamo Biosciences while it was climbing from $10.30 to as high as $23.04 in less than four months…

I have many more I can tell you about.

But you’re probably wondering…

If your life’s work is in science and medicine – why are you talking about a new “offshoot” created by marijuana stocks?

Well, the answer is very simple.

I’ve been studying curative properties of cannabis for some time now. And everything I’ve seen tells me:

Cannabis is – Hands Down – the Single Most Important Medical Treatment of the 21st Century.

I’m talking on a scale of “penicillin” in terms of the number of people it could impact…

And “insulin” in terms of the quality of life it can offer people who are suffering.

Everything from chronic pain… to Parkinson’s… to epileptic seizures… to Alzheimer’s… to glaucoma… to cancer… and beyond…

Scientific studies are now showing the healing components found in cannabis can treat it all – naturally and without the side effects associated with typical pharmaceutical drugs.

But here’s the thing:

Those bags of marijuana you can buy at corner dispensaries, take home, and smoke, vape, or eat, can make you high…

That’s yesterday’s “pot” story…

Right now, scientists have something MUCH better…

I’m talking about real, pharmaceutical-grade cannabinoid medications scientifically formulated and clinically proven to treat a long line of specific ailments.

Targeted and controlled dosages…

Made primarily with the non-psychoactive ingredients, which means you won’t get high when you take them.

Some are calling it a “coming of age” for medical marijuana.

I think it’s much bigger…

What this really amounts to is the pharmacological “takeover” of the multibillion-dollar medical marijuana industry…

An industrial “coup d’état” that’s unprecedented in the history of American business.

Because think about it…

What stands a better chance in the market?

An unproven and unapproved mixture of weed and/or oil you have to smoke or ingest that’s been “formulated” by some self-proclaimed expert in a warehouse and peddled at your local pot dispensary…

Or FDA-approved, marijuana-based medicine developed by brilliant pharmaceutical scientists who’ve spent a king’s ransom on the research needed to create effective, SAFE, dosage-controlled drugs aimed at treating specific conditions and diseases…

All backed by the real, multiple-phase clinical studies and double-blind testing required by the FDA to ensure safety and efficacy…

Until now, the few marijuana-based drugs to be approved featured synthetic forms of cannabis made in a laboratory – like dronabinol, which can have serious side effects and is addictive.

Epidiolex is the very first drug approved by the FDA made from the PURE ingredients of the marijuana plant – which have little or no side effects or addictive qualities.

Why is this such a watershed event for the dozens of tiny companies currently working on marijuana-based treatments?

It’s very simple.

When a branch of the federal government the scope, size, and power of the FDA…

With its $4.7 billion annual budget…

And a mandate to protect and promote public health through the control and supervision of, among other things, prescription medication…

Issues a statement that essentially says:

“We’ve been wrong the whole time… Cannabis really does work…”

And then gives its full blessing to a pharmaceutical-grade drug made up of the very plant the government has waged war on for decades…

It marks a pivotal moment in history.

For people like you who see it coming, this is HUGE.

New companies – like the five I’ll tell you about in a moment – are lining up to be a part of this massive new “offshoot” industry.

Not only because of the billions of dollars up for grabs within the $1.112 pharmaceutical industry…

Or because banks and other investment groups now have the “green light” to pour billions of dollars into this new industry…

It’s also because of the amazing – and proven – medicinal benefits of marijuana that have the potential to transform the pharmaceutical industry…

By providing safe and effective alternatives to the dangerous and highly addictive treatments millions of patients are on right now.

It’s the “sea change” people are talking about.

For years, pot’s medicinal effects were anecdotal. We didn’t know why they worked or how…

But now we do.

Just recently the National Academies of Sciences, Engineering, and Medicine examined more than 10,000 scientific studies done on marijuana over the years…

There was conclusive evidence that the cannabinoids in the marijuana plant can be an effective treatment for chronic pain and other ailments.

Much of what we know now about the effect of cannabis on human health is thanks to the work of an Israeli chemist by the name of Dr. Raphael Mechoulam…

Dr. Mechoulam and his team discovered something called the endocannabinoid – or “EC” – system…

The physiologic network inside of all of us that regulates things like movement, memory, appetite, and pain.

He discovered our bodies actually produce natural cannabinoids – like the ingredients found in natural marijuana – to keep our endocannabinoid system in check.

But when there’s a deficiency, and your body can’t supply enough cannabinoids to your system, various forms of pain and physical complications can occur…

Like migraines, fibromyalgia, and irritable bowel syndrome, to name a few.

And because your EC system is responsible for regulating neurotransmitter systems as well – more serious diseases, such as Alzheimer’s symptoms and Parkinson’s disease may also be related to EC system deficiencies.

Marijuana and the more than 100 known cannabinoids found in the plant serve to replenish and rejuvenate this network…

Thus, relieving pain and other maladies caused by a weakened or deficient EC system.

It’s as if our bodies were made to use cannabinoids to combat pain and promote healing…

And cannabis was put here on Earth for us to use as a natural cure!

Now the FDA’s approval of Epidiolex just opened the floodgates in a massive way.

That’s because there are estimated to be over 120 ailments where pharmaceutical marijuana can play a curative role.

One of the markets where pharmaceutical cannabis can have an immediate impact is the $70 billion pain market.

More than 1.5 billion people world-wide suffer from chronic pain.

That’s roughly one out of every five people on the planet…

And the current treatment of choice for pain?

For many, it’s opioids…

But opioids are highly addictive – and they’re killing people.

Over 2 million Americans are dependent on opioids and can’t get off them, reports CNN.

Many experts say cannabis is the answer.

The cannabinoids found in cannabis have been shown in studies to work just as well as opioids on most pain.

But, again…

Forget about smoking, vaping, or eating it…

As one industry expert said, it’s hard to imagine a less efficient way to put the healing power of cannabis to work.

Dosages are impossible to regulate because you can’t control how deeply people inhale or how long they hold the smoke in their lungs before exhaling…

Potency and quality of the cannabis you’re using varies greatly from crop-to-crop.

Formulations are not scientifically controlled, so they don’t target any specific disease.

Not to mention the negative impacts smoking marijuana can have on your respiratory system – since “deeper draws” and longer holding time in the lungs can result in five times the concentration of carbon monoxide, three times the tar, and higher levels of ammonia and hydrogen cyanide.

That’s why there’s no doubt:

The real future of medical marijuana is in slow-release, standard-dosage, pharmaceutical-grade tablets…

Powerful cannabinoid formulations that target SPECIFIC pain by zeroing in on specific receptors in the brain and body…

With consistent dosages that are more potent, longer-lasting, and much safer than smoking.

Again, this is not “pie in the sky.”

It’s happening now.

FDA’s approval of Epidiolex is just the beginning.

Barry Sherman, the founder of one of the largest privately held generic drug firms in the world, said recently:

“Pills with regulated dosages unique to individuals is a game changer in the industry and a disrupter to big pharma…”

Ascher Shmulewitz, a noted cardiologist and medical engineer says medical research and pharmaceuticals are already focusing more and more on marijuana…

“The marijuana market will be divided… Pills for medicine, joints for pleasure.”

Even the man who created OxyContin – that notorious opioid-based pain killer – now believes marijuana holds the answer:

“Cannabinoids are genuine therapeutic agents,” he says. “Medical cannabis can save us from painkillers.”

Former Republican House Speaker John Boehner was once firmly in the anti-marijuana camp.

Now, even he sees and supports the medical benefits of marijuana.

He said he changed his mind after watching marijuana help a close friend deal with back pain… and learning what it can do for veterans suffering from chronic pain, PTSD, and other ailments…

“My thinking on cannabis has evolved,” he told The New York Times.”

Regarding Mr. Boehner’s full embrace of marijuana, one analyst said:

“It is difficult to overstate the impact of this monumental event for the U.S. cannabis sector.”

Smart investors are paying attention.

Here’s GW Pharmaceutical’s stock price the last few months, as it was becoming clear FDA approval was close…

And the company announced that estimated annual sales of Epidiolex could reach $1.6 billion in the coming years.

The stock shot from $105 a share to $155 – a mammoth gain for a company with a $4.3 billion market cap.

Impressive? Sure.

Will GW go higher still?

Maybe…

But companies like GW Pharmaceuticals are NOT where the big money will be made as the pharmaceutical industry’s takeover of medical pot unfolds.

It’s the tiny companies that have been working on cannabis-based pharmaceutical cures and treatments for years – in some cases decades – all in anticipation of this day…

Because when they go up in value by $1.3 billion, the way GW did, the profits can be exponentially large.

In a moment, I’ll detail five of these companies I’m following right now that could deliver millions of dollars to investors savvy enough to recognize the enormity of this opportunity.

They’re all still very small – which can mean big, fast gains when breakthroughs “go public.”

The largest I’m following has a market cap of just $153 million.

That’s 28 timessmaller than GW Pharmaceuticals.

One way to estimate the potential future size of a company is to multiply potential sales by the industry average price-to-sales ratio…

Which for biotech companies across the board is a ratio of 7.02 to 1…

That means, for every extra $1 a biotech company generates in sales… its valuation increases by around $7…

With this formula in mind, it’s possible GW Pharmaceuticals could double when $1.6 billion is added to its ledger.

Not bad…

But take a look at what happens when you add $1.6 billion in potential sales to one of the much smaller companies I’m about to discuss with you…

$1.6 billion in sales…

Times the industry average price to sales ratio of 7.02.

Suddenly it’s no longer a $153 million micro-cap stock…

It’s now worth $11.2 billion…

More than 75 times the current size…

Which, in turn, gives you a chance to turn $2,500 into $186,600!

And remember…

That’s the BIGGEST company I’ll share with you today.

Another very promising company has a mere $14 million market cap.

Add $1.6 billion in sales to that company and you’re looking at a staggering 819-fold growth…

And a chance to turn $2,500 into over $2 million!

Of course, not all small stocks will grow in line with price-to-sales ratios…

But with so much NEW REVENUE pouring into TINY companies…

Not to mention the billions of dollars in institutional money that’s been sitting on the sidelines…waiting for today’s “green light” from the FDA that lets people know the time to investin pharmaceutical cannabis companies has begun…

There’s no doubt the stock price of SMALLER companies, like the ones I’m tracking, will surge much higher than an established company like GW.

That’s why I’m so excited to tell you about all these new, smaller, smarter companies…

Companies that have been working on various forms of pharmaceutical cannabis for many years – and offer you far greater profit potential.

Some are trading for as little as $1 per share right now.

And that’s where things get really exciting.

A new prescription drug with mass appeal… or a new drug that treats a disease or condition for which there is no cure or FDA-approved treatment…

Drugs like these can easily eclipse the $1.6 billion per year in sales GW Pharmaceuticals is estimating for Epidiolex.

Take OxyContin – just one of many opioids on the market. It was a $2 billion-per-year drug in its heyday.

Sales for the anti-inflammation drug Stelara are over $4 billion a year.

Eylea – a drug used to treat macular degeneration – sales are over $8 billion a year…

And for big drugs like Humira, sales can top $18 billion a year!

Imagine if a tiny $107 million-market-cap company – like another of the stocks I’ll talk about shortly – hits a grand slam home run with an $18 billion-a-year cannabis-based drug?

Now you’re looking at the potential for 1,180-times growth…

Enough to turn your $2,500 stake into $2,952,000!

A windfall like this would be very unusual to say the least. And a lot of things would have to go right for any stock to see this kind of growth.

But in an industry as NEW and FAST-GROWING as cannabis pharmaceuticals, gains like this are possible.

In fact, I’m releasing full details on the latest new recommendations.

The first company is trading for around $1.

And it’s secret weapon?

It’s a pharmaceutical industry insider who, until a few years ago, headed up one of most successful privately-held pharmaceutical companies in the world…

But more importantly…

He was one of the scientists responsible for bringing OxyContin to the U.S. market back in 1995.

Now, you probably know…

OxyContin, Vicodin, Fentanyl – they’re just some of the opioid drugs responsible for the current addiction crisis.

And medical marijuana is being touted as the solution.

So, as you can imagine…

The fact that someone so close to the opioid controversy is now looking to profit – it’s a little controversial to say the least.

You can look at it that way and ignore this opportunity on principle.

But if you do, I think you could be leaving millions of dollars on the table.

Whatever you may think of his past work, this man and the team that surrounds him – they know the drug business.

They know the science behind successful treatments…

They know what it takes to get a drug to market…

They know how to get doctors to prescribe them…

And they know what it takes to rack up billions in sales.

And he’s made it no secret that his new company’s plan is to replicate OxyContin’s success… starting with the drug itself.

You see, the secret behind OxyContin’s success was not its superiority over earlier painkilling drugs like morphine.

It was the control-release technology the company had developed for its long list of pills that allowed medication to work longer by dispersing the active ingredient more quickly.

The company’s plan is to do the same with cannabinoids.

By continually developing and improving formulations from the more than 90 active, beneficial cannabinoid ingredients, some of which have been shown to be effective on many types of pain…

And then combining those formulations with advanced and highly accurate dosage technologies that provide long-lasting and safe relief…

The money here could be insane.

Over $70 billion is spent on opioid substance abuse treatments – 80% of that by Americans, according to CNBC.

The U.S. opioid market alone is expected to reach $18.4 billion in sales by 2020.

And now, with all the backlash and new restrictions on prescribing opioid drugs, doctors are more desperate than ever for a pain medication that’s as effective as opioids…

But without the side effects, addictive properties, or growing risk of legal liabilities associated with prescribing it.

So it leaves very little doubt…

The company that harnesses the immense power of pharmaceutical-grade cannabinoids to control pain has the potential to sell billions.

Plus, the “sustained-release” tablet technology this company is working on can be used for FAR MORE than just pain medicine…

Every cannabis drug for which there is an accepted medical application could benefit from the tablet technology this company is developing!

In other words, the sky’s the limit here.

Even if this little company can captureone-tenth of just the $18 billion pain market…

You could see its valuation soar – from under $150 million today…

To as much as $12.6 billion.

That could mean an immediate “pop” from under $1 in the stock price to as much as $47…

And the potential to turn a $2,500 stake into $210,000 or more.

Of course, I can’t guarantee gains will be that big. Nobody can. And even though my research shows this company has substantial expertise in drug-delivery technology, you can never predict how the market will respond.

That said – even a fraction of those gains would be considered a “nice win” for any investor.

Here’s something else to remember.

We don’t need to see these drugs “on the shelves” tomorrow to start seeing these gains.

Now that the FDA has legitimized medical cannabis by greenlighting Epidiolex… we could see billions of dollars in new investment money rushing into tiny “first-mover” companies like this one.

I’ll tell you everything you need to know:

Everything about the management team…

The different marijuana-based treatments and technologies it’s developing…

The partnerships it’s forming… the “hard science” behind the work it’s doing…

And of course, I’ll give you easy-to-follow, step-by-step instructions for making the trade, including my crucial “buy up to” price and risk-management strategies – which I always recommend you follow when it comes to volatile small stocks like the ones I’m talking about today.

But remember…

Pain and drug delivery is just one part of the massive $1.112 trillion market for pharmaceutical-grade marijuana.

Rheumatoid ARTHRITIS, ALZHEIMER’S, and PARKINSON’S disease, GLAUCOMA, and MACULAR DEGENERATION could be in the $46 billion range in the coming years.

National Institutes of Health Research is also now learning that marijuana extracts may help kill certain CANCER cells and reduce the proliferation of others.

Other clinical and preclinical trials are underway for:

Immune diseases like HIV/AIDS and Multiple Sclerosis (MS)…

Inflammation…

Epileptic seizures and muscle spasms…

Mental disorders…

Anxiety and depression…

PTSD…

Hepatitis C…

Substance abuse, and…

Brain stroke recovery.

So, there is no shortage of opportunities.

The second stock on my short list tackles one of these.

This one has the potential to double very quickly… possibly before the month is out. I’ll tell you why in a moment.

This new drug involves a very promising cannabis-based treatment for a rare neurological condition that can lead to Tourette’s Syndrome.

Most people think of Tourette’s as that “cursing disease…”

But in reality, it’s an affliction that affects 1 in 100 people… mostly children.

These kids develop uncontrollable tics and spasms that rob them of a normal childhood – and can lead to alienation, bullying, and psychological problems later in life.

Right now, synthetic drugs like Haloperidol and Fluphenazine are used to address the disease’s symptoms…

But there can be serious side effects for these types of drugs – everything from dizziness and nausea to tremors and trouble breathing, and even to more severe adverse events listed in “black box warnings” required by the FDA.

On the other hand, Phase 2 clinical studies showed that not only was this new cannabinoid-based drug well tolerated by a majority of study participants…

But also, they experienced a very noteworthy 21% decrease in the disease’s major symptom – facial tics – across the entire test sample.

So, based on testing so far, we know it works… and it’s much safer than traditional treatments.

But here’s your immediate opportunity.

Phase 2 clinical trials are one of the most important and potentially lucrative phases of the FDA study process.

I can’t tell you how many stocks I’ve seen soar on positive results at this critical “mid” trial stage.

It’s when investors learn – for the very first time – that a drug has the potential to work on actual patients… and it’s safe.

And when you’re dealing with a new drug and a disease for which there is no cure and no FDA-approved treatment – investors tend to get very excited once news gets out.

I’ve seen many, many examples of this.

Look at AnaptysBio Inc…

It rocketed from $35 to $128 after its dermatitis drug reported Phase 2 success – including a near 100% gain the day results were announced.

Esperion Therapeutics went from right around $16 in the days before its hypercholesterolemia drug’s Phase 2 study results were announced – to a high of $115 within a few months.

Sage Therapeutics soared from $89 a share to $167 in three days… on the way to a recent high of $192… all on positive news from this phase.

And these are not “small” companies.

Sage Therapeutics was a $4 billion company when study results were reported – and the stock still more than doubled on the Phase 2 news.

So, you can imagine…

When the market gets hold of positive news like this – involving a company that’s more than 250 times smaller – there’s no telling how high the stock could go.

Aquinox Pharmaceuticals might give us the best clue…

Its market cap stock was under $50 million when it delivered positive results in a Phase 2 study for interstitial cystitis, a painful condition of the bladder.

Just days before the August 6 announcement, Aquinox was $1.51 a share…

Less than three weeks later, the stock had shot to $22.10 – a 1,363% gain.

A chance to turn a $2,500 stake into a very fast $31,575!

But the potential for a short-term windfall from the Phase 2 findings is just one of the ways to cash in.

The company estimates the annual market opportunity for Tourette’s drugs in the U.S. at about $1.5 billion.

That’s a substantial revenue stream for any biotech company…

But for a company with a mere $15 million market cap – like this one has…

This could translate into HUGE gains once the first ever FDA-approved drug comes to market.

Even if it only captures half that market, that’s $750 million in potential sales.

And using our industry average price-to-sales metric for predicting the value of a company… that could put it at $5.2 billion…

351 times the size it is today…

And give you the potential to turn every $2,500 stake into a massive $877,500 windfall.

There’s no limit to the gains when you have small companies in play in such a fast-moving industry.

Another company I’m following is working on a cannabis-based drug to treat Fragile X Syndrome.

Of course, these past gains don’t mean they’re guaranteed to happen again. It’s not every day that a stock shoots this high, this fast… and you have to be very lucky to catch the ones that do.

But I think you’ll agree…

Even a fraction of these gains would be life-changing.

And consider that the next wave of cannabis companies could be staking their claim in the huge $1.112 trillion pharmaceutical market…

And with pharmaceutical marijuana now a reality…

The potential here is massive to say the least.

I, for one, am not going to let this historic opportunity go by.

And, frankly, I don’t want you to miss out either.

That’s why it’s so critical that you take out a subscription to Biotech Insider Alertright away.

Biotech Insider Alert is the culmination of my life’s work.

It’s where I leverage my decades of experience, scientific knowledge and connections in the medical profession to help you get in on the ground floor of medical breakthroughs.

By “ground floor” I mean small companies on the verge of major breakthroughs that can make you rich.

Like another pharmaceutical cannabis innovator you’ll learn about as a Biotech Insider Alert subscriber…

It’s tiny – and the upside is huge.

This one has a drug that treats Graft vs Host Disease or GvHD… a rare complication that occurs when transplanted donor stem cells meant to attack problem cells attack the patient’s healthy organs as well.

When I say “rare,” it’s because few people have donor cells transplanted. But, incredibly, an estimated 70% who do contract GvHD.

That’s what happened to a patient named “Greg.”

He had a blood stem cell transplant for cutaneous T-cell lymphoma – a type of blood cancer that attacks the skin – right around the time his daughter was born.

The new cells were successful in attacking the cancer cells and everything looked great…

But six months later, his legs began to swell – a sign new cells were also attacking healthy parts of his body.

That’s the cruelty of the disease. Just when you think everything is fine – disaster can strike.

Greg’s condition worsened over time… to the point where his skin was so sensitive and painful that he couldn’t let his daughter hug him.

The little company I’m following could be a Godsend for people like Greg who are fighting to overcome the debilitating and often deadly effects of GvHD.

Its brand-new cannabis-based drug has just been granted valuable orphan status by the FDA.

In early Phase 2 studies of the drug in the treatment of GvHD, patients were provided daily doses for seven days prior to transplantation… 30 days afterwards… and monitored for 16 months.

While on the treatment, just 12% developed Grade II-IV acute GvHD – the most serious forms of GvHD – compared to the historical 46%.

That’s an astonishing 283% improvement…

But that’s not all…

Study patients also had fewer skin and gastrointestinal issues compared with the control group…

And the marijuana-based treatment was safe and well tolerated, which is an absolute necessity for any drug seeking FDA approval.

This is all great news for GvHD sufferers…

And exciting for investors too.

Global Data, a medical consulting firm, says the GvHD market is growing – and could reach $544 million in the coming years.

That’s a sizable market for a company with a mere $21 million market cap and a share price of just 14 cents.

If the company could capture even half of that market…

This little company’s market cap could soar to $1.9 billion…

A potential 90-to-1 windfall that could turn a small $2,500 stake into a staggering $226,600.

Again, these are incredible projections.

But in biotech stocks especially, a new treatment where none exist can lead to massive gains.

Take Illumina…

That stock rocketed from $33 a share to $75 on the success of its work in genome research back in 2009…

Now Illumina is a $269-per-share company, turning every $2,500 invested early on into $17,100.

Jazz Pharmaceuticals is even more impressive…

It received orphan status for Defibrotide – a drug designed to help fight a disease that obstructs the tiny veins in the liver.

The result?

Jazz jumped from a low of 55 cents a share… to over $192 a share.

That’s a ridiculous 348-to-1 gain – good enough to turn a $2,500 stake into $870,000!

But with the “pharmaceuticalization” of cannabis, you won’t just see one or two windfall opportunities like this a year…

There’s an entire industry of tiny companies waiting to cash in.

Another tiny company I’m watching is working on a cannabis-based drug to treat Epidermolysis Bullosa…

A potentially deadly disease that makes skin extremely fragile, causing it to tear from very minor friction or trauma.

If you’ve heard the term “butterfly children,” it’s referring to the fragile state of children with Epidermolysis Bullosa – or “EB.”

They have to be constantly protected from their environment.

The slightest friction can produce agonizing wounds that can cover up to 75% of their bodies.

And every day, it can take up to three hours to clean and dress new wounds, which can occur from simply turning over during sleep.

There’s no recognized treatment or cure.

This company’s new drug could be the first.

It features cannabinoids specifically selected to impact keratin levels, making skin less fragile and less susceptible to easy tearing.

There’s also a secondary cannabinoid that’s been shown to reduce inflammation, decrease itching and pain, and promote skin regeneration – which cannabinoids such as CBD are well known for.

Even though only about 2,000 children get the disease each year, the estimated market for a new EB drug is right around $1.3 billion.

That’s HUGE for the tiny, 79-cent-per-share company that’s working on this “orphan” disease.

Again, when you run the numbers, the potential here is massive…

An 86-to-1 return based on the EB opportunity potential alone.

And the chance to turn a $2,500 stake into $215,000.

But this company has something else going for it…

A “secret weapon” that could transform how quickly and efficiently cannabis-based drugs are discovered and developed.

It’s a brand-new technology that combines massive amounts of data on over 90 cannabinoids along with proprietary algorithms that can quickly identify cannabinoid combinations that are likely to have an effect on specific diseases.

So imagine you’re a small biotech or drug company…

You have a disease or unmet medical need you want to tackle…

You punch in key biometric information relative to the disease…

Hit enter… and presto…

Using its massive database and proprietary algorithms, it identifies a combination of cannabinoids most likely to have the best therapeutic effect on a variety of diseases and ailments.

This technology could lead to a tidal wave of new marijuana-based drugs…

Save decades of research time…

Save tens of millions of dollars in new drug-research costs…

And not only will the company use the technology to identify targets for its own proprietary drug research…

But there’s also the potential for a multiple-billion-dollar revenue stream from licensing agreements as well.

One major investment research firm predicts this technology will make this little biotech… “one of the sector’s next big stars.”

This is one of those tiny “under $1 stocks” that could go on to deliver life-changing gains.

It reminds me of Jazz Pharmaceuticals less than a decade ago… the company I just told you about.

Using research technology and a focus on new treatments for diseases with unmet needs – Jazz became one of the biggest biotech success stories in history…

Delivering gains big enough to turn $2,500 into $870,000.

Now…

I’ve given you a quick overview of just a few of the tiny companies leading the way in the “pharmaceuticalization” of marijuana and medical cannabis:

There’s the “OxyContin mastermind…”

Who says the drug-delivery technology and treatments his new company is working on could be “even bigger” than the $35 billion success he had developing and marketing the opioid pain medication OxyContin.

Potential on a $2,500 stake here could be as high as $210,000.

I told you about the very small biotech working on a cannabis-based Tourette’s drug and the Phase 2 trial release.

That one has the potential to turn $2,500 into a whopping $877,500.

There’s the company with the potential Fragile X Syndrome treatment that could deliver a $149,300 windfall.

There’s the little company working on a Graft-versus-Host Disease treatment that could give you a very nice $225,000 win.

And the more than 348-to-1 windfall you could see from the tiny company with the very promising EB treatment and that amazing proprietary drug-discovery technology…

Good enough to potentially turn a $2,500 play into as much as $870,000 when all is said and done.

This is where I give you progress updates on our open recommendations…

And answer your most asked questions, so you are constantly kept up to date on everything that’s happening.

Then, whenever it’s time to close out one of our opportunities, I release a Real-Time Profit Alert.

This helps you maximize any returns. And for these small companies especially, I’ll have my recommended “buy up to” price. I never want my readers paying more than they should if they want to make a new investment.

To ensure you never miss one of these fast payouts, I suggest you take advantage of my text message notification system.

It sends your cell phone a “ping” whenever I release a new Investment Research Report or Real-Time Profit Alert via email.

Just tap it… check your email… see the trade I’m recommending… hear my thoughts about it… and, if you decide you want to be a part of it, simply execute the trade on your smartphone from anywhere.

While optional, I highly recommend this, since the smaller stocks I follow can move fast…

And believe me – when one of these tiny pharmaceutical marijuana stocks starts moving, even a 10-minute delay can cost you thousands in potential profits.

As you can see, I’ve built my Biotech Insider Alert to be incredibly comprehensive.

Yes, there’s a massive opportunity in pharmaceutical marijuana – in my view, potentially the biggest we’ve ever seen in biotech.

But you’ll also learn about other companies working on more traditional drug treatments and medical marvels being developed by tiny labs and pharmaceutical firms around the world.

Companies like Illumina…

A virtually unknown firm that invented a system for genetic sequencing…

That drove the stock up 3,679%.

Or Regeneron Pharmaceuticals… which experienced a 7,650% surge thanks to a drug portfolio that included a treatment for macular degeneration.

These are opportunities that can make millionaires out of everyday investors…

And my years of experience and hard-won knowledge help me uncover companies like these.

I’m sure you can appreciate that my Biotech Insider Alert research service is intended for people who are serious about seeing how to make BIG money from this explosive industry.

So it’s definitely not cheap.

The regular retail cost to join is $5,000 for one year – and considering the massive profits we’re going after, it’s worth every penny of that and much more.

And as my readers love to point out, your very first win could easily repay your membership fee for you – and much, much more.

But these gains are trifling compared to what I’m expecting from this exciting marijuana “spin off” industry…

Remember – this is not your typical opportunity.

It’s brand new…

So new it didn’t even officially exist until the FDA approved the first ever pure cannabis-based pharmaceutical drug on June 25.

It’s just getting started.

The big institutional money isn’t anywhere close to being “all in” yet.

But that’s about to change… in a hurry.

It’s like a “perfect storm” is forming. And it’s happening right now.

Learn about all these amazing companies…

And start positioning yourself for what I believe will be an avalanche of life-altering profits…

Why just 500 people?

It relates to what I’ve been saying.

I’m not focused on biotech heavyweights with $50 billion market caps.

That’s not where the big money for investors is – especially in an industry as new and burgeoning as pharmaceutical cannabis.

I focus my vetting on ground-floor opportunities…

Small companies with huge upside.

And no sector of the biotech world is so brimming with tiny companies on the verge of explosive growth than the companies ready to stake their claim in the massive $1.112 trillion pharmaceutical-drug market.

This is historic.

To make sure you’re a part of it, you’ll get everything – including…

Full coverage on the “pharmaceuticalization” of marijuana – including complete research dossiers on the companies I’ve told you about today…

Full research reports on additional pharmaceutical cannabis “first movers” as they stake their claim in this trillion-dollar industry.

Access to all of my research from other medical discoveries on the Biotech Insider Alert website…

Full and instant access to my current portfolio of Biotech Insider Alert recommendations…

As I uncover new companies at the forefront of this brand-new offshoot of this massive $1.112 trillion industry.

So the next move is yours.

Just click the BIG BUTTON at the bottom of this page.

It will take you to a short “membership acceptance form” where you can review everything and make your final decision.

And don’t forget…

If I don’t come through with 10-1 on your money within the year – you pay nothing.

But don’t delay.

Given the “perfect storm” forming for pharmaceutical marijuana right now…

And the massive amount of money set to pour into this brand-new industry as a result of this first-ever historic FDA decision…

The 500 membership spots available today won’t last long.

I’m Ernie Tremblay.

I look forward to working with you.

Copyright – 2016 Money Map Press, LLC. The Money Map Press is a publishing company that does not act as a personal investment advisor for any specific individual. Nor do we advocate the purchase or sale of any security or investment for any specific individual. The proprietary recommendations and analysis we present to readers is for the exclusive use of subscribers. Readers should be aware that although our track record is highly rated, and has been legally reviewed for presentation in this invitation, investment markets have inherent risks and there can be no guarantee of future profits. Likewise, our past performance does not assure the same future results. Warning: The past performance of any trade whether actual or hypothetical is not necessarily an indication of future results. Stocks, futures, currencies, commodities, CFDs, options and all types of investment trading can have large potential rewards, but also carry large potential risks. We make absolutely no representation that gains or losses demonstrated in services published by Money Map Press LLC are likely or achievable. Hypothetical trading examples also cannot possibly take into account the impact of liquidity or buyer and seller demand, and do not allow for slippage and associated trading costs and concerns. One must be aware of the risks and be willing to accept them in order to invest in the markets. One should never trade with money that one cannot afford to lose, and one must accept that there will be losses, and one must be able to sustain these losses, both from a financial as well as an emotional perspective. Recommendations are for the exclusive use of subscribers and can change at any time. This work is based on SEC filings, current events, interviews, corporate press releases, and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility.

Recent Tweets

Contact Us

Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Money Map Press, 1125 North Charles Street, Baltimore MD 21201, USA.